Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY – Get Free Report)’s share price was up 6.9% on Thursday. The stock traded as high as $38.5220 and last traded at $38.5220. Approximately 2,460 shares traded hands during mid-day trading, a decline of 94% from the average session volume of 41,980 shares. The stock had previously closed at $36.05.
Analyst Ratings Changes
Separately, Zacks Research upgraded Otsuka from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 9th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Otsuka currently has a consensus rating of “Moderate Buy”.
Read Our Latest Stock Report on Otsuka
Otsuka Stock Up 1.3%
The company’s 50-day moving average is $37.28 and its 200 day moving average is $35.59. The company has a market capitalization of $41.51 billion, a PE ratio of 15.52, a P/E/G ratio of 2.74 and a beta of 0.09. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.65 and a current ratio of 2.21.
Otsuka (OTCMKTS:OTSKY – Get Free Report) last released its quarterly earnings data on Friday, July 31st. The company reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.51 by $0.19. Otsuka had a net margin of 15.50% and a return on equity of 12.86%. The business had revenue of $4.41 billion during the quarter, compared to analyst estimates of $3.95 billion. Otsuka has set its FY 2026 guidance at 2.119-2.119 EPS. As a group, analysts anticipate that Otsuka Holdings Co., Ltd. – Unsponsored ADR will post 2.23 EPS for the current year.
About Otsuka
Otsuka Holdings Co, Ltd. is a Japan-based healthcare company that oversees the Otsuka Group’s pharmaceutical, nutraceutical and consumer health businesses. The company’s operations are primarily conducted through subsidiaries, including Otsuka Pharmaceutical Co, Ltd., which researches, develops, manufactures and markets prescription medicines, over-the-counter products and health-related foods.
Otsuka’s pharmaceutical activities focus on areas such as psychiatry, oncology, cardiovascular and renal medicine, and several other specialized therapeutic fields.
Further Reading
- Five stocks we like better than Otsuka
- Rocket Lab’s Neutron Delay Leaves Wall Street Bullish But Raises the Stakes for 2027
- ManpowerGroup Stock Sinks on Q3 Results, But Fundamentals Stay Solid
- Does the AI Selloff Put Alphabet’s Breakout in Doubt?
- Bank Earnings Are Mixed—These 2 ETFs Offer Very Different Paths to a Recovery
Receive News & Ratings for Otsuka Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otsuka and related companies with MarketBeat.com's FREE daily email newsletter.
